CARTCO: CAR T Cell Therapy Related Cardiovascular Outcomes

University College London Hospitals (Other)
Overall Status
Recruiting ID

Study Details

Study Description

Brief Summary

This will be a cohort study of all patients receiving Cluster of Differentiation 19 (CD19)-specific CAR T cell therapy for relapsed/refractory B cell haematological malignancies. Patients will receive cardiac assessment and have serum cardiac biomarkers, ECG, transthoracic echocardiogram and cardiac magnetic resonance imaging performed at baseline prior to CAR T cell therapy, 7 days post CAR T cell infusion, and 3 months post CAR T cell infusion. Abnormalities in these cardiac investigations will be used to demonstrate cardiac injury and identify which patients are most at risk of developing cardiac injury related to CAR T cell therapy.

Detailed Description

CD19-specific chimeric antigen receptor (CAR) T cells are a novel therapy for relapsing or refractory blood cancers, which have delivered a significant improvement in the rates of complete and partial remission. However, they are associated with toxicities, with some of early evidence suggestive of cardiovascular involvement. Despite this, the full extent of cardiovascular toxicity is poorly understood.

This research study seeks to understand the cardiac safety of CAR T cells in patients who receive this therapy as part of standard care for relapsed/refractory B-cell blood cancer. They will be assessed for cardiovascular risk factors via history, blood biomarkers, and cardiac imaging tests. These parameters will be repeated at 7 days following administration of the CAR T cells or if there are signs of cardiovascular deterioration, and again at 3 months follow up.

The aim is to predict the cohort most at risk of cardiovascular toxicity, and demonstrate evidence of cardiac injury on the cardiac imaging scans.

Study Design

Study Type:
Anticipated Enrollment :
150 participants
Observational Model:
Time Perspective:
Official Title:
Chimeric Antigen Receptor (CAR) Cell Therapy Related Cardiovascular Outcomes
Actual Study Start Date :
Jan 18, 2021
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Outcome Measures

Primary Outcome Measures

  1. Detected abnormalities - Composite [3 months]

    The primary outcome is a composite of detected abnormalities on biomarkers, transthoracic echocardiogram (TTE), or Cardiac magnetic resonance (CMR) following CAR T cell infusion.

Secondary Outcome Measures

  1. Detected abnormalities - Individual [3 months]

    The secondary outcome measures includes a composite of detected abnormalities of factors on cardiac biomarkers (troponin and N-terminal pro B-type natriuretic peptide) , electrocardiogram (ECG) changes and acute heart failure.

Eligibility Criteria


Ages Eligible for Study:
16 Years and Older
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  • Patients with capacity, (aged 16 and older)

  • Undergoing CAR T cells for treatment for relapsing or refractory haematological malignancies

Exclusion Criteria:
  • Patients under 16 years

Contacts and Locations


Site City State Country Postal Code
1 University College London Hospitals London United Kingdom

Sponsors and Collaborators

  • University College London Hospitals


None specified.

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Derek Yellon, Professor, University College London Hospitals Identifier:
Other Study ID Numbers:
  • 20/SC/0301
First Posted:
Nov 23, 2021
Last Update Posted:
Nov 23, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Keywords provided by Derek Yellon, Professor, University College London Hospitals
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 23, 2021